The Tuberous Sclerosis Alliance grants the Manuel R. Gomez Award to individuals who have made a significant impact on our understanding of TSC in research and/or have impacted the delivery of clinical care for individuals with TSC.
The TS Alliance is deeply saddened by the passing of Sue Povey, whose work contributed to some of the largest discoveries in the genetics of TSC. Our heartfelt condolences go out to Professor Povey’s friends and family.
Please help us welcome Dean Aguiar, PhD, to the TS Alliance team! Dean is our new Director of Preclinical Research. He will lead the Preclinical Consortium’s future efforts, including the goal to partner with additional companies and academic researchers to help find new ways to treat the multiple, severe and sometimes life-threatening manifestations of TSC. He will also oversee other consortium objectives, including increasing the diversity of models available as well as adding models for TSC-associated neuropsychiatric disorders, an additional epilepsy model and human cell-based models.
The Tuberous Sclerosis Alliance grants the Manuel R. Gomez Award to individuals who have made a significant impact on our understanding of TSC in research, and/or have impacted the delivery of clinical care for individuals with TSC.
2017 was a very productive year for advancing the science of tuberous sclerosis complex (TSC)! A very small sampling of our scientific community’s major accomplishments are highlighted below. The TS Alliance thanks all our grantees, collaborators, reviewers, conference attendees, International Scientific Advisory Board members, and Professional Advisory Board members for making these achievements possible.
The TS Alliance has just submitted the Voice of the Patient report to the US Food and Drug Administration (FDA). This report summarizes the Patient-Focused Drug Development (PFDD) meeting that we held on June 21. The PFDD meeting was designed to communicate to FDA the impacts of TSC on individuals’ daily lives, what types of treatment benefits make the most impact on peoples’ lives, and individuals’ and caregivers’ perspectives on how well available therapies are working. The report is now available on our PFDD page.
TS Alliance Chief Scientific Officer Steve Roberds, PhD, serves on the Advisory Council of the National Institute of Neurological Disorders and Stroke. During the open session of the Advisory Council meeting on September 7, 2017, NINDS staff discussed several upcoming funding opportunities: As part of an NIH-wide initiative to enhance diversity in the research workforce, NINDS soon plans to reissue a RFA for NIH Blueprint D-SPAN (F99/K00) award with a due date in December (see the previous RFA for reference). The purpose of the D-SPAN program is to support a defined pathway across career stages for outstanding graduate students who…
Nominations are being accepted until April 15, 2017, for the Manuel R. Gomez Award. This award is given in memory of Manuel R. Gomez, MD, the “Father of TSC” in the USA. Dr. Gomez provided care and compassion for hundreds of individuals with TSC during his career, and he sparked interest in the diagnosis and clinical care of individuals with TSC. A nominee should be someone who has made a significant impact on our understanding of TSC in research and/or impacted the delivery of clinical care for individuals with TSC.
Welcome to the new TSC Alert, a monthly electronic newsletter for TSC researchers. It provides updates on TSC research resources, conferences and clinical studies, as well as news that may be relevant to investigators in the field.